|
DoP extends bid submission timeline for selection of consultancy firm to execute PRIP Scheme
|
|
Our Bureau, New Delhi
September 04 , 2024
|
|
|
The Department of Pharmaceuticals (DoP) has extended the bid submission and opening dates for the selection of consulting firm for strategy development and implementation of the Promotion of Research and Innovation in Pharma MedTech (PRIP) sector scheme, due to technical reasons.
The bid submission end date has been extended from August 31, 2024 to September 5, 2024 at 5 pm, said the Department in a corrigendum to the tender document. The other terms and conditions in the tender document remains the same as per the tender published on July 24, 2024, it added.
The bid opening date, according to the latest decision, has been fixed as September 7, at 11 am as against the previously fixed September 2, at 11 am.
The timeline for submission of Request for Proposal (RFP) was earlier extended from August 14 to August 31, and the bid opening date from August 16 to September 2, 2024, through an announcement in early August.
The Department, during the time, also relaxed the pre-qualification criteria allowing the agencies or consultants who have experience handling or completing order value of more than Rs. 4 crore (for each order) in domestic market and $1 million for international market during the last 10 years.
Earlier, the bidders who have completed or handled projects with each order value of more than Rs, 8 crore for domestic and $1 million for international projects during the last 10 years only were eligible to apply for the job.
Similarly, the scoring criteria to be used for evaluation was fixed to the effect that the bidder must submit the number of projects it handled with each order value of more than Rs 8 crore during the last 10 years. The evaluation was to provide one mark per project subject to a maximum of 10 projects.
However, this has also been relaxed through a corrigendum, so that the bidders can enlist the number of projects with each order value of more than Rs. 4 crore during the last 10 years. The scoring criteria has also been changed, so that two marks per project subject to a maximum of five projects are to be calculated during evaluation.
The Department also revised the provision for payment of consultants, to clarify that all payments to the consultant shall be made in Indian Rupees on a quarterly basis, contingent upon the achievement of performance deliverables. The exchange risk, if any, shall be borne by the consultant.
The Department, on July 24, invited tenders from eligible bidders for providing consultancy services for the PRIP sector scheme, announced last year to support research and development (R&D) and innovation in pharma, medical devices and animal health segments.
The time-period of the assignment will be two years from the date of award of the contract extendable to one more year on monthly remuneration basis on same terms and conditions.
The consultants are expected to support the DoP in administration, management and supervision of the scheme, and monitor and review the progress of selected projects under the scheme and appraise the progress of the scheme to the department.
The DoP has notified the Scheme PRIP with an outlay of Rs. 5,000 crore in August, 2023 and had initiated efforts to identify the Project Management Agency (PMA) from central public sector undertakings and public financial institutes. The proposed appointment of consultants is also part of these efforts to execute the scheme.
The scheme has two components comprising strengthening of research infrastructure through establishment of seven National Institutes of Pharmaceutical Education & Research (NIPERs) as Centres of Excellence (CoEs) in specific specialisations at a tentative cost of Rs. 700 crore and promotion of research in Pharma-MedTech sector by providing financial assistance for research in six priority areas - new chemical and biological entities, and natural products; complex generics and biosimilars; precision medicines; medical devices; orphan drugs; and drug development for antimicrobial resistance (AMR).
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|